- Home
- EXOZ vs RAPT Comparison
EXOZ vs RAPT Comparison
Compare EXOZ & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXOZ
- RAPT
- Stock Information
- Founded
- EXOZ 2014
- RAPT 2015
- Country
- EXOZ United States
- RAPT United States
- Employees
- EXOZ N/A
- RAPT N/A
- Industry
- EXOZ
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- EXOZ
- RAPT Health Care
- Exchange
- EXOZ NYSE
- RAPT Nasdaq
- Market Cap
- EXOZ 138.0M
- RAPT 117.5M
- IPO Year
- EXOZ N/A
- RAPT 2019
- Fundamental
- Price
- EXOZ $10.47
- RAPT $0.78
- Analyst Decision
- EXOZ
- RAPT Hold
- Analyst Count
- EXOZ 0
- RAPT 7
- Target Price
- EXOZ N/A
- RAPT $5.00
- AVG Volume (30 Days)
- EXOZ 8.4K
- RAPT 845.4K
- Earning Date
- EXOZ 05-15-2025
- RAPT 05-08-2025
- Dividend Yield
- EXOZ N/A
- RAPT N/A
- EPS Growth
- EXOZ N/A
- RAPT N/A
- EPS
- EXOZ N/A
- RAPT N/A
- Revenue
- EXOZ N/A
- RAPT N/A
- Revenue This Year
- EXOZ N/A
- RAPT N/A
- Revenue Next Year
- EXOZ N/A
- RAPT N/A
- P/E Ratio
- EXOZ N/A
- RAPT N/A
- Revenue Growth
- EXOZ N/A
- RAPT N/A
- 52 Week Low
- EXOZ $8.50
- RAPT $0.75
- 52 Week High
- EXOZ $23.99
- RAPT $8.58
- Technical
- Relative Strength Index (RSI)
- EXOZ N/A
- RAPT 30.91
- Support Level
- EXOZ N/A
- RAPT $0.75
- Resistance Level
- EXOZ N/A
- RAPT $0.98
- Average True Range (ATR)
- EXOZ 0.00
- RAPT 0.10
- MACD
- EXOZ 0.00
- RAPT -0.03
- Stochastic Oscillator
- EXOZ 0.00
- RAPT 5.89
About EXOZ EXOZYMES INC
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.